204268-09-7

Basic information

• Product Name: (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester
• Synonyms: (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester
• CAS NO: 204268-09-7
• Molecular Weight: 436.505
• Mol File: 204268-09-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester(204268-09-7)
• EPA Substance Registry System: (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid methyl ester(204268-09-7)

Safety Data

• Hazardous Substances Data: 204268-09-7(Hazardous Substances Data)

Upstream product

• 178306-52-0 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 
• 178306-51-9 (S)-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid 
• 177036-78-1 (S)-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid methyl ester 
• 7417-21-2 2-(3,4-dimethoxyphenyl)ethyl alcohol 

Downstream Products

• 204267-33-4 Feloprentan 
• 204268-10-0 (S)-3-<2-(3,4-dimethoxyphenyl)ethoxy>-2-hydroxy-3,3-diphenylpropionic acid 

Relevant articles and documents

Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists

The invention relates to carboxylic acid derivatives of the formula I where the radicals have the meanings stated in the description, and to their use as drugs.

Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2(4,6- dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist

Structural variation of the endothelin A-selective antagonist (S)-3- methoxy-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 135252) led to analogues which retain ETA affinity but exhibit substantial ET(B) affinity as well. The most active derivative obtained is (S)-3-[2- (3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3- diphenylpropionic acid (LU 302872), which can be prepared in enantiomerically pure form in eight steps via an acid-catalyzed transetherification. It has a K(i) = 2.15 nM for binding to the ETA receptor and a K(i) = 4.75 nM for binding to the ET(B) receptor, is orally available, and antagonizes the big ET-induced blood pressure increase in rats and the big ET-induced bronchospasm in guinea pigs each time at a dose of 10 mg/kg.